Entellus Medical, a Maple Grove, Minn.-based developer of novel, less invasive treatments for chronic conditions of sinusitis, has completed its 30m Series D financing.
The company recently launched FinESS Sinus Treatment, a less-invasive therapy that breaks the cycle of chronic sinusitis with immediate relief and lasting results.
The round was led by new investor Essex Woodlands Health Ventures and supported by existing investors Split Rock Partners and SV Life Sciences.
The funds will bhe used to expand the Entellus’s sales and customer support teams, accelerate efforts to allow patients to be treated in an office-based setting and allow the company to launch its innovative technologies nationwide in 2010 and prepare to market internationally.
FinSMEs
17/11/2009